The useful distinction
‘Peptide’ is a chemistry category, not a quality stamp. Some peptides are established medicines with labels and human data. Others are research compounds or wellness-market products with limited clinical evidence.
Evidence labels we use
The Glow Diary separates FDA-approved medicines, approved but narrow-indication therapies, investigational drugs, emerging clinical signals, and limited-human-evidence peptides. The label travels with the claim.
Common peptide topics
BPC-157, sermorelin, tesamorelin, CJC-1295/ipamorelin, and epitalon all appear in wellness conversations, but they do not have the same evidence base, legal status, or safety clarity.
Red flags in peptide marketing
Be cautious with universal protocols, disease-treatment claims without labels, ‘research use’ products pitched to consumers, vague sourcing, no monitoring plan, and influencer claims that skip human outcomes data.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.